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INTRODUCTION
Zoledronic acid (ZA), a potent nitrogen-containing bisphos-
phonate, has been used in daily practice for the prevention of 
skeletal-related events that are caused by bone metastasis from 
diverse tumors [1-3]. Furthermore, recent clinical trials pro-
vided solid evidence that ZA effectively inhibits the loss of 
bone minerals in postmenopausal women with breast cancer 
or premenopausal women with chemotherapy-induced amen-
orrhea [4-6]. 
In addition, since many preclinical studies have demon-
strated the antitumor effect of ZA in preventing or palliating 
metastatic tumors [7-10], clinical data on ZA use in breast 
cancer have been evaluated. Moreover, studies showing the 
clinical benefits of ZA therapy in patients with bone metasta-
ses have been reported [1,11]. Although the routine use of ZA 
as an adjuvant treatment in unselected breast cancer patients 
is still controversial, a growing body of evidence has shown 
that combined ZA and endocrine therapy can improve clini-
cal outcomes in patients with breast cancer and low estrogen 
levels, who are also menopausal or receiving ovarian suppres-
sion [5,12,13].  
On the basis of the above findings, the use of ZA as an add-
itional adjuvant treatment has become increasingly wide-
spread. Previously, we showed that ZA can prevent bone min-
eral loss, which is accelerated by aromatase inhibitors in post-
menopausal Korean women with breast cancer [14]. In the 
present study, we aimed to assess the survival benefit of com-
bined ZA and upfront aromatase inhibitor therapy in post-
menopausal Korean women with breast cancer.
Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer 
Patients Receiving Aromatase Inhibitors
Sung Gwe Ahn*, Sung Hyun Kim*, Hak Min Lee, Seung Ah Lee1, Joon Jeong
Department of Surgery, Yonsei University College of Medicine, Seoul; 1Department of Surgery, Eulji University College of Medicine, Seoul, Korea
ORIGINAL ARTICLE
J Breast Cancer 2014 December; 17(4): 350-355 http://dx.doi.org/10.4048/jbc.2014.17.4.350
Purpose: A growing body of evidence indicates that zoledronic 
acid (ZA) can improve the clinical outcome in patients with 
breast cancer and low estrogen levels. In the present study, we 
aimed to investigate the survival benefit of ZA administration in 
postmenopausal Korean women with breast cancer who were 
also receiving aromatase inhibitors. Methods: Between January 
2004 and December 2010, 235 postmenopausal breast cancer 
patients undergoing aromatase inhibitor therapy were investigat-
ed. All patients were postmenopausal, as confirmed by labora-
tory tests. Of these patients, 77 received adjuvant upfront ZA for 
at least 1 year in addition to conventional adjuvant treatment. 
The remaining 158 patients never received ZA and were treated 
according to the St. Gallen guidelines. Results: The baseline 
characteristics for ZA treatment were not different between the 
two groups. The median follow-up time was 62 months, and the 
patients who received ZA in addition to aromatase inhibitors 
showed a better recurrence-free survival compared to those who 
received aromatase inhibitors alone (p=0.035). On multivariate 
analysis, the patients who received ZA showed a better recur-
rence-free survival independent of the tumor size, nodal status, 
progesterone receptor, and histological grade. For this model, 
Harrell c index was 0.743. The hazard ratio of ZA use for recur-
rence-free survival was 0.12 (95% confidence interval, 0.01–
0.99). Conclusion: Our findings suggest that upfront use of ZA as 
part of adjuvant treatment can offer a survival benefit to post-
menopausal breast cancer patients receiving aromatase inhibitor 
treatment.
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METHODS
Patient selection
We identified 252 hormone receptor-positive women who 
received upfront adjuvant aromatase inhibitors after surgery 
between January 2004 and December 2010 at a single institute. 
Of the 252 patients, 17 were excluded because ZA was admin-
istered for less than a year. Finally, this study enrolled 235 post-
menopausal women. Postmenopausal status was defined as the 
absence of menstruation for at least 12 months before surgery, 
and serum follicle stimulating hormone levels greater than 30 
mIU/mL. Patients who underwent bilateral salpingo-oopho-
rectomy prior to the diagnosis of breast cancer were not ex-
cluded. All patients received anastrozole (1 mg), letrozole (2.5 
mg), or exemestane (25 mg) daily. Ten patients switched aro-
matase inhibitors due to drug intolerance. In total, 158 patients 
received the aromatase inhibitors alone and 77 patients re-
ceived aromatase inhibitors in combination with ZA. ZA treat-
ment was administered more than twice for at least 1 year. In 
such cases, 4 mg of ZA was administered intravenously every 3 
to 6 months. None of these patients received oral bisphospho-
nates. All the patients were treated with or without chemother-
apy according to the St. Gallen guidelines.
For the immunohistochemical evaluation, formalin-fixed, 
paraffin-embedded tissue sections from surgical specimens 
were stained with antibodies for the estrogen receptor (ER; 
Novocastra, Newcastle upon Tyne, UK), the progesterone re-
ceptor (PR; Novocastra), human epidermal growth factor re-
ceptor 2 (HER2; Ventana Medical Systems, Tucson, USA), 
and Ki-67 (Dako, Glostrup, Denmark). ER and PR statuses 
were determined by nuclear staining, which was graded from 
0 to 8 using the Allred score [15]. The results were categorized 
as positive when the total score, expressed as the sum of the 
proportion score and intensity score, was 3 or more. For 
HER2 evaluation, membranous staining was graded as fol-
lows: score 0, 1+, 2+, and 3+ [16]. HER2 status was deemed to 
be positive with a score of 3+ and negative with a score of 0 or 
1+. Tumors with a score of 2+ underwent fluorescence in situ 
hybridization using the PathVysion HER2 DNA Probe Kit 
(Abbott-Vysis, Des Plaines, USA).
The tumors were classified according to the American Joint 
Committee on Cancer staging system, seventh edition. The 
modified Scarf-Bloom-Richardson grading system was used 
for tumor grading. Adjuvant systemic therapy and/or radio-
therapy were considered according to standard guidelines 
based on patient age, primary tumor characteristics, and axil-
lary lymph node status. All patients received aromatase inhib-
itors as adjuvant endocrine treatment. The Institutional Re-
view Board of Gangnam Severance Hospital, Korea, approved 
the study (Local Institutional Review Board number: 3-2014-
0917) in accordance with good clinical practice guidelines and 
the Declaration of Helsinki.
Statistical analysis
Age is presented in this study as a median value with a range, 
and compared using the Mann-Whitney U-test. Discrete vari-
ables were compared by the chi-square test. The primary end-
point was recurrence-free survival (RFS). RFS was measured 
from the date of the first curative surgery to the date of the 
first locoregional recurrence or distant metastasis. The Ka-
plan-Meier method was utilized to estimate RFS. Metastasis-
free survival (MFS) was calculated to the date of the first dis-
tant metastasis. Estimated survival curves were compared us-
ing the log-rank test. Significant prognostic factors associated 
with RFS were selected using Harrell c statistic [17], and a Cox 
proportional hazards regression model was applied for multi-
variate survival analysis. The SPSS version 18 (SPSS Inc., Chi-
cago, USA) and R softwares (http://www.r-projet.org) were 
used to perform these analyses. Statistical significance was de-
fined by a p-value < 0.05.
RESULTS
Baseline characteristics
The median age of 235 postmenopausal women was 56 
years (range, 43–91 years). Natural menopause occurred in 
228 women (97.0%), and seven women underwent bilateral 
salpingo-oophorectomy prior to breast cancer diagnosis. All 
patients began upfront aromatase inhibitor therapy as adju-
vant endocrine treatment after breast surgery or completion 
of adjuvant chemotherapy. In total, 77 patients received ZA in 
addition to aromatase inhibitors, while 158 women only re-
ceived aromatase inhibitors. The median duration of ZA infu-
sions was 45 months (range, 13–69 months), while the medi-
an number of ZA infusions was 11 (range, 2–21). None of the 
ZA-treated patients had osteonecrosis of the jaw.
Demographics, clinicopathological characteristics, and ad-
juvant treatment between the two groups were similar (Table 
1). In addition, there was no difference in the use of aromatase 
inhibitors between the groups (Table 2). Ten women switched 
to other aromatase inhibitors because of adverse effects. One 
patient from the ZA-untreated group received upfront ex-
emestane for 5 years. The regimens of neoadjuvant/adjuvant 
chemotherapy did not differ between the two groups. Detailed 
information regarding adjuvant or neoadjuvant chemother-
apy is provided in Supplementary Table 1.
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Survival outcome
The median follow-up time was 62 months, when 14 wom-
en had tumor recurrences. At the time of the first relapse, 
three women had locoregional recurrences and 11 had distant 
metastases. Of the three women with locoregional recurrences 
at first relapse, two patients had distant metastases. During 
the follow-up period, three deaths occurred.
For all the patients, the 5-year RFS rate was 95.8%. The 
5-year RFS rates for patients with and without ZA were 98.5% 
and 94.6%, respectively. The 5-year RFS rate for ZA-treated pa-
tients was significantly higher than that for ZA-untreated pa-
tients (p= 0.022) (Figure 1A). Concurrently, MFS was signifi-
Table 1. Baseline characteristics according to treatment of zoledronic 
acid
Characteristic
ZA-treated
(n=77)
No. (%)
ZA-untreated
(n=158)
No. (%)
p-value
Age (yr)* 56 (42–27) 57 (37–91) 0.236†
Cause of menopause 0.794
  Naturally 75 (97.4) 153 (96.8)
  BSO 2 (2.6) 5 (3.2)
Years since menopause 0.211
   <1 9 (11.7) 18 (11.4)
   1–4 19 (24.7) 41 (25.9)
   >4 49 (63.6) 99 (62.7)
T stage 0.151
   T1 57 (74.0) 101 (63.9)
   T2 19 (24.7) 55 (34.8)
   T3 1 (1.3) 2 (1.3)
N stage 0.211
   N0 50 (64.9) 90 (56.0)
   N1 20 (26.0) 55 (34.8)
   N2 7 (9.1) 9 (5.7)
   N3 0 4 (3.5)
Stage 0.084
   I 39 (50.6) 59 (37.3)
   II 31 (40.3) 85 (53.2)
   III 7 (9.1) 14 (9.5)
Histologic grade‡ 0.809
   I or II 61 (88.4) 130 (87.2)
   III 8 (11.6) 19 (12.8)
Estrogen receptor 0.434
   Positive 74 (96.1) 148 (93.7)
   Negative 3 (3.9) 10 (6.3)
Progesterone receptor 0.936
   Positive 64 (83.1) 132 (84.7)
   Negative 13 (16.9) 26 (15.3)
HER2§ 0.585
   Positive 13 (16.9) 30 (19.0)
   Negative 64 (83.1) 128 (81.0)
Adjuvant chemotherapy 0.504
   Treated 47 (61.0) 91 (57.6)
   Untreated 30 (39.0) 67 (42.4)
Adjuvant radiotherapy 0.080
   Treated 39 (50.6) 62 (39.2)
   Untreated 38 (49.4) 96 (60.8)
ZA=zoledronic acid; BSO=bilateral salphingo-oophorectomy; HER2=human 
epidermal growth factor receptor 2.
*Median (range); †Mann-Whitney U-test; ‡Data with missing values; §HER2 
positive was defined by 3 positive on immunohistochemistry or amplification 
on fluorescence in situ hybridization.
Table 2. Use of aromatase inhibitors according to zoledronic acid treat-
ment
Agent
ZA-treated
No. (%)
ZA-untreated
No. (%)
p-value
Anastrozole (n=95) 37 (48.1) 58 (36.7) 0.170
Letrozole (n=129) 39 (50.6) 90 (57.0)
Exmestane (n=1) 0 1 (0.6)
Two agents (n=10)* 1 (1.3) 9 (5.7)
ZA=zoledronic acid.
*Switch one aromatase inhibitor to another aromatase inhibitor due to intoler-
ability.
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Figure 1. Kaplan-Meier plots according to zoledronic acid treatment. 
The p-value was calculated using log-rank test. (A) Recurrence-free 
survival (p=0.035). (B) Metastasis-free survival (p=0.037).
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cantly better for ZA-treated women than for ZA-untreated 
women (p= 0.029) (Figure 1B). Among ZA-treated women, 
one case of distant metastasis was observed. In contrast, among 
the ZA-untreated women, three had locoregional recurrences 
and 10 had distant metastases at first relapse (Figure 2). Add-
itionally, two of the three women with locoregional recurrenc-
es in the ZA-untreated group experienced distant metastasis.
In the univariate analysis of RFS, lower histological grade 
(p= 0.012) and PR positivity (p= 0.019) were associated with 
a better outcome (Supplementary Table 2). Multivariate analy-
sis using a Cox proportional hazards regression model sug-
gested that the use of ZA (adjusted hazard ratio, 0.12; 95% 
confidence interval, 0.02–0.99) was an independent prognos-
tic factor for RFS, whereas PR positivity (adjusted hazard ratio, 
0.29; 95% confidence interval, 0.09–0.98) was also associated 
with a decreased risk of tumor recurrence (Table 3). These dif-
ferences were independent of tumor size, lymph node involve-
ment, and histological grade. For this model, the Harrell c in-
dex was 0.743.
DISCUSSION
In Korea, the use of ZA for the preservation of bone miner-
al density in postmenopausal women treated with adjuvant 
aromatase inhibitors has been limited. We previously showed 
that the use of ZA can preserve bone mineral density in post-
menopausal women treated with aromatase inhibitors [14]. In 
the present study, we provide evidence for the clinical benefits 
of adjuvant ZA therapy in postmenopausal women receiving 
aromatase inhibitors. Our data also demonstrate the antitu-
mor effect of ZA in the inhibition of distant metastasis in 
postmenopausal breast cancer patients. One of the reasons 
why our data supports the clinical benefits of ZA is that the 
majority of the study population (63.0%) had true menopau-
sal status. The median age of our study population was 56 
years and 57% of the patients had experienced menopause 
more than 4 years ago.
Our finding that RFS was improved by the combined use of 
ZA and aromatase inhibitors in postmenopausal women is 
consistent with previous reports. Although the AZURE trial 
[12] failed to demonstrate the survival benefit of routine adju-
vant ZA treatment among postmenopausal patients, the 
5-year invasive disease-free survival rates differed significantly 
according to ZA treatment (78.2% in the ZA group and 71.0% 
in the control group). In the Austrian Breast Cancer Study 
Group Trial-12 (ABCSG-12) [13], the addition of ZA to en-
docrine therapy resulted in an absolute reduction of 3.2% 
points and a relative reduction of 36% in the risk of disease 
progression, as compared to endocrine therapy without ZA. 
In addition, the Zometa-Femara Adjuvant Synergy Trial (ZO-
FAST) [5] showed that ZA administration in postmenopausal 
women receiving letrozole is associated with improved dis-
ease-free survival compared to those receiving letrozole alone. 
Taken together, these trials suggest that ZA in combination 
with endocrine therapy induces a consistent improvement of 
survival outcomes in women with low estrogen levels and is 
in concordance with our results.
To evaluate the direct antitumor effect of ZA in the clinical 
setting, several studies have attempted to test ZA as a compo-
nent of neoadjuvant therapy. On the basis of short-term 
changes in biomarkers, several studies have provided evidence 
of the direct antitumor effect of ZA and the possible molecu-
lar mechanism for the biological effect of ZA [18,19]. Among 
the trials based on additional ZA treatment for neoadjuvant 
therapy, the FemZone trial [20] reported a trend suggesting a 
better response for letrozole in combination with ZA than let-
rozole alone. Coleman et al. [21] reported that addition of ZA 
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Table 3. Multivariate analysis for disease-free survival using Cox regres-
sion hazard model*
Variable* Comparison Hazard ratio (95% CI) p-value
T stage T2 and T3 (n=71) Reference
T1 (n=133) 0.56 (0.07–4.48) 0.587
Nodal status Positive (n=82) Reference
Negative (n=122) 0.39 (0.04–4.05) 0.432
PR Negative (n=147) Reference
Positive (n=32) 0.27 (0.08–0.84) 0.024
Histologic grade III (n=19) Reference
I and II (n=168) 0.23 (0.07–0.77) 0.017
Zoledronic acid Untreated (n=67) Reference
Treated (n=137) 0.12 (0.02–0.97) 0.046
PR=progesterone receptor.
*Presented variables are selected using Harrell c statistic. In this analysis, Har-
rell c index was 0.729.
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to chemotherapy enhances the clinical response. Conversely, 
the neoadjuvant chemotherapy (TAC) with or without ZA 
(NEOZOTAC) trial [22] suggested that the addition of ZA to 
neoadjuvant chemotherapy did not improve the pathological 
or clinical response to chemotherapy. For postmenopausal 
women in the NEOZOTAC trial, the benefit of treatment with 
ZA was not statistically significant. Nevertheless, larger stud-
ies are warranted for the evaluation of the antitumor effect of 
ZA when it is administered as a component of neoadjuvant 
therapy in breast cancer patients, particularly in women with 
estrogen-poor environment. 
Inherent limitations are associated with the retrospective 
nature of this study. Our study was not a randomized con-
trolled study, and thus, selection bias may have affected pa-
tient classification for ZA treatment. In addition, uncontrolled 
adjuvant treatment can attenuate our findings. Heterogeneous 
regimens of neoadjuvant/adjuvant chemotherapy might po-
tentially influence the survival outcome. A small sample size 
and very good outcomes in our population were other limita-
tions. Although osteonecrosis of the jaw was not identified in 
ZA-treated patients, adverse effects of ZA administration were 
not systematically reviewed. Moreover, the duration of ZA in-
fusions varied among the ZA-treated patients. Despite these 
limitations, our findings add to the growing body of data in 
support of adding ZA to aromatase inhibitor therapy in post-
menopausal women. In addition, there was no difference in 
baseline characteristics and adjuvant treatment based on ZA 
treatment.
In conclusion, our findings suggest that upfront use of ZA 
might offer a survival benefit for postmenopausal patients re-
ceiving aromatase inhibitors.
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